Drugs firm Aspen is to pay £8m to the NHS after an investigation into the supply of a life-saving drug to thousands of patients.
The Competition and Markets Authority (CMA) said the firm offered to make the payment following an investigation.
The CMA said it suspects competition law was broken after Aspen paid two rivals to stay out of the market.
This left Aspen as the only UK supplier of fludrocortisone and able to set prices without competition, it added.
Aspen may also have to pay an additional £2.1m fine if the CMA formally decides the company broke the law.
Andrea Coscelli, the CMA’s chief executive, said it was “unacceptable for the NHS – and the taxpayers who fund it – to have to pay millions of pounds more than